Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2026-06-03 Merger & Acquisition
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
S-4/A
Merger & Acquisition Classification · 88% confidence The document is an Amendment No. 2 to a Form S-4 Registration Statement under the Securities Act, containing the merger agreement, exchange ratio, and proxy/prospectus materials for the VYNE–Yarrow Bioscience merger and related shareholder votes. It is not simply an announcement or proxy notification but the formal SEC filing registering securities in connection with a merger transaction. This aligns with the Merger & Acquisition (MA) category.
2026-06-03 English
FORM 8-K
Investor Presentation Classification · 92% confidence The document is a Form 8-K under Item 7.01—Regulation FD Disclosure—reporting the furnishing of an investor presentation (Exhibit 99.1) and referencing its availability on the company’s investor website. This clearly corresponds to providing an investor presentation, fitting the “Investor Presentation” category.
2026-05-21 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
S-4/A - VYNE Therapeutics Inc. (0001566044) (Filer)
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It includes detailed information about a proposed merger between VYNE Therapeutics Inc. and Yarrow Bioscience, Inc., including terms of the merger, stock exchange ratios, financing, and shareholder meeting proposals related to the merger. The presence of merger agreement details, stock issuance proposals, and proxy statement references indicates this is a filing related to M&A activity rather than a general annual report, earnings release, or other categories. Therefore, the document fits the M&A Activity category.
2026-04-28 English
S-4 - VYNE Therapeutics Inc. (0001566044) (Filer)
M&A Activity Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It contains detailed information about a proposed merger between VYNE Therapeutics Inc. and Yarrow Bioscience, Inc., including terms of the merger, stock exchange ratios, financing, and shareholder meeting proposals related to the merger. The presence of merger agreement details, stock issuance proposals, and shareholder voting items indicates this is a filing related to M&A activity. It is not an annual report, earnings release, or proxy statement alone, but a registration statement specifically for the merger transaction. Therefore, the appropriate classification is M&A Activity (TAR).
2026-03-31 English
10-K - VYNE THERAPEUTICS INC. (0001566044) (Filer)
Annual Report FY 2025
2026-02-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.